Finance

Biopharmaceutical company reports third quarter results

Published in Blood Weekly, November 18th, 2004

Nabi Biopharmaceuticals announced that strong sales performance for PhosLo (calcium acetate) and Nabi-HB (Hepatitis B Immune Globulin - Human) drove an increase in net cash provided by operating activities in the third quarter of 2004.

The company said that the gross margin earned on product sales exceeded 50% for the second quarter in a row. Despite increasing its investment in research and clinical trial support for StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine) by $12.3 million from 2003 levels, operating cash flow totaled a positive $5.2 million in the 2004 third quarter. Led by increases in year-to-date biopharmaceutical sales, including the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry